Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 9
Submit an article Journal homepage
227
Views
64
CrossRef citations to date
0
Altmetric
Review

Gene therapy for mucopolysaccharidosis

Katherine P Ponder Washington University School of Medicine, Departments of Internal Medicine and Biochemistry and Molecular Biophysics, 660 South Euclid Avenue, St. Louis, MO 63110, USA +1 314 362 5188; +1 314 362 8813; [email protected]
&
Mark E Haskins University of Pennsylvania, Department of Pathobiology, School of Veterinary Medicine, 3800 Spruce Street, Philadelphia, PA 19104, USA
Pages 1333-1345 | Published online: 29 Aug 2007

Bibliography

  • NEUFELD EF, MUENZER J: The mucopolysaccharidoses. In: Metabolic and Molecular Basis of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw Hill: New York, USA (2001):3421-3452.
  • BAEHNER F, SCHMIEDESKAMP C, KRUMMENAUER F et al.: Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. (2005) 28(6):1011-1017.
  • DESNICK RJ: Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis. (2004) 27(3):385-410.
  • HOOGERBRUGGE PM, BROUWER OF, BORDIGONI P et al.: Allogeneic bone marrow transplantation for lysosomal storage diseases. The European group for bone marrow transplantation. Lancet (1995) 345(8962):1398-1402.
  • SIFUENTES M, DOROSHOW R, HOFT R: A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol. Genet. Metab. (2007) 90(2):171-180.
  • MUENZER J, WRAITH JE, BECK M et al.: A Phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. (2006) 8(8):465-473.
  • HARMATZ P, GIUGLIANI R, SCHWARTZ I et al.: Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase III, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. (2006) 148(4):533-539.
  • PETERS C, SHAPIRO EG, ANDERSON J et al.: Hurler syndrome. II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The storage disease collaborative study group. Blood (1998) 91(7):2601-2608.
  • STABA SL, ESCOLAR ML, POE M et al.: Cord–blood transplants from unrelated donors in patients with Hurler's syndrome. N. Engl. J. Med. (2004) 350(19):1960-1969.
  • VELLODI A, YOUNG E, COOPER A, LIDCHI V, WINCHESTER B, WRAITH JE: Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. (1999) 22(5):638-648.
  • ERSKHOVITZ E, YOUNG E, RAINER J et al.: Bone marrow transplantation for Maroteaux–Lamy syndrome (MPS VI): long-term follow-up. J. Inherit. Metab. Dis. (1999) 22(1):50-62.
  • SARDIELLO M, ANNUNZIATA I, ROMA G, BALLABIO A: Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. Hum. Mol. Genet. (2005) 14(21):3203-3217.
  • FRALDI A, BIFFI A, LOMBARDI A et al.: SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem. J. (2007) 403(2):305-312.
  • CARDONE M, POLITO VA, PEPE S et al.: Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum. Mol. Genet. (2006) 15(7):1225-1236.
  • YOUNG LS, SEARLE PF, ONION D, MAUTNER V: Viral gene therapy strategies: from basic science to clinical application. J. Pathol. (2006) 208(2):299-318.
  • HODGES BL, CHENG SH: Cell and gene-based therapies for the lysosomal storage diseases. Curr. Gene Ther. (2006) 6(2):227-241.
  • ELLINWOOD NM, VITE CH, HASKINS ME: Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J. Gene Med. (2004) 6(5):481-506.
  • CHEN ZY, HE CY, EHRHARDT A, KAY MA: Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo Mol. Ther. (2003) 8(3):495-500.
  • ARONOVICH EL, BELL JB, BELUR LR et al.: Prolonged expression of a lysosomal enzyme in mouse liver after sleeping beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J. Gene Med. (2007) 9(5):403-415.
  • SANDS MS, DAVIDSON BL: Gene therapy for lysosomal storage diseases. Mol. Ther. (2006) 13(5):839-849.
  • XU L, MANGO RL, SANDS MS, HASKINS ME, ELLINWOOD NM, PONDER KP: Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol. Ther. (2002) 6(6):745-758.
  • LIU Y, XU L, HENNIG AK et al.: Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol. Ther. (2005) 11(1):35-47.
  • CHUNG S, MA X, LIU Y, LEE D, TITTIGER M, PONDER KP: Effect of neonatal administration of a retroviral vector expressing α-l-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol. Genet. Metabol. (2007) 90(2):181-192.
  • DALY TM, OHLEMILLER KK, ROBERTS MS, VOGLER CA, SANDS MS: Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. (2001) 8(17):1291-1298.
  • DALY TM, VOGLER C, LEVY B, HASKINS ME, SANDS MS: Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA (1999) 96(5):2296-2300.
  • DONSANTE A, LEVY B, VOGLER C, SANDS MS: Clinical response to persistent, low-level β-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J. Inherit. Metab. Dis. (2007) 30(2):227-238.
  • HARTUNG SD, FRANDSEN, JL, PAN D et al.: Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human a-L-iduronidase gene. Mol. Ther. (2004) 9(6):866-875.
  • MA X, LIU Y, TITTIGER M et al.: Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol. Ther. (2007) 15:889-902.
  • PONDER KP, MELNICZEK JR, XU L et al.: Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. USA (2002) 99(20):13102-13107.
  • SLEEPER MM, FORNASARI B, ELLINWOOD NM et al.: Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII. Circulation (2004) 110(7):815-820.
  • MANGO RL, XU L, SANDS MS et al.: Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol. Genet. Metab. (2004) 82(1):4-19.
  • WANG B, O'MALLEY TM, XU L et al.: Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol. Genet. Metab. (2006) 87(1):8-21.
  • TRAAS AM, WANG P, MA X et al.: Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol. Ther. 33:1423-1431.
  • SFERRA TJ, BACKSTROM K, WANG C, RENNARD R, MILLER M, HU Y: Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. (2004) 10(3):478-491.
  • DALY TM, OKUYAMA T, VOGLER C, HASKINS ME, MUZYCZKA N, SANDS MS: β-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther. (1999) 10(1):85-94.
  • FRISO A, TOMANIN R, ALBA S et al.: Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J. Gene Med. (2005) 7(11):1482-1491.
  • ROSS CJ, BASTEDO L, MAIER SA, SANDS MS, CHANG PL: Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum. Gene Ther. (2000) 11(15):2117-2127.
  • MOULLIER P, BOHL D, HEARD JM, DANOS O: Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat. Genet. (1993) 4(2):154-159.
  • WOLFE JH, SANDS MS, HAREL N et al.: Gene transfer of low levels of β-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol. Ther. (2000) 2(6):552-561.
  • SHULL RM, LU X, MCENTEE MF, BRIGHT RM, PEPPER KA, KOHN DB: Myoblast gene therapy in canine mucopolysaccharidosis. I: abrogation by an immune response to α-L-iduronidase. Hum. Gene Ther. (1996) 7(13):1595-1603.
  • WOLFE JH, SANDS MS, BARKER JE et al.: Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature (1992) 360(6406):749-753.
  • HOFLING AA, DEVINE S, VOGLER C, SANDS MS: Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol. Ther. (2004) 9(6):856-865.
  • ZHENG Y, ROZENGURT N, RYAZANTSEV S, KOHN DB, SATAKE N, NEUFELD EF: Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol. Genet. Metab. (2003) 79(4):233-244.
  • ZHENG Y, RYAZANTSEV S, OHMI K et al.: Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB. Mol. Genet. Metab. (2004) 82(4):286-295.
  • LUTZKO C, KRUTH S, ABRAMS-OGG AC et al.: Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine α-L-iduronidase deficiency. Blood (1999) 93(6):1895-1905.
  • LUTZKO C, OMORI F, ABRAMS-OGG AC et al.: Gene therapy for canine α-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Hum. Gene Ther. (1999) 10(9):1521-1532.
  • MEERTENS L, ZHAO Y, ROSIC-KABLAR S et al.: In utero injection of α-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. Hum. Gene Ther. (2002) 13(15):1809-1820.
  • MILLER DG, WANG PR, PETEK LM, HIRATA RK, SANDS MS, RUSSELL DW: Gene targeting in vivo by adeno-associated virus vectors. Nat. Biotechnol. (2006) 24(8):1022-1026.
  • VOGLER C, LEVY B, GRUBB JH et al.: Overcoming the blood–brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA (2005) 102(41):14777-14782.
  • KOBAYASHI H, CARBONARO D, PEPPER K et al.: Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. (2005) 11:776-789.
  • HENNIG AK, LEVY B, OGILVIE JM et al.: Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. (2003) 23(8):3302-3307.
  • CHEN F, VITRY S, HOCQUEMILLER M, DESMARIS N, AUSSEIL J, HEARD JM: α-L-iduronidase transport in neurites. Mol. Genet. Metab. (2006) 87(4):349-358.
  • PASSINI MA, LEE EB, HEUER GG, WOLFE JH: Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci. (2002) 22(15):6437-6446.
  • XIA H, MAO Q, DAVIDSON BL: The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. (2001) 19(7):640-644.
  • DESMARIS N, VEROT L, PUECH JP, CAILLAUD C, VANIER MT, HEARD JM: Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. (2004) 56(1):68-76.
  • CRESSANT A, DESMARIS N, VEROT L et al.: Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. (2004) 24(45):10229-10239.
  • BOSCH A, PERRET E, DESMARIS N, HEARD JM: Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. (2000) 1(1):63-70.
  • LIU G, CHEN YH, HE X et al.: Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol. Ther. (2007) 15(2):242-247.
  • STEIN CS, GHODSI A, DERKSEN T, DAVIDSON BL: Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. (1999) 73(4):3424-3429.
  • BROOKS AI, STEIN CS, HUGHES SM et al.: Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA (2002) 99(9):6216-6221.
  • VITE CH, PASSINI MA, HASKINS ME, WOLFE JH: Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. (2003) 10(22):1874-1881.
  • PASSINI MA, WATSON DJ, VITE CH, LANDSBURG DJ, FEIGENBAUM AL, WOLFE JH: Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of β-glucuronidase-deficient mice. J. Virol. (2003) 77(12):7034-7040.
  • LIU G, MARTINS I, WEMMIE JA, CHIORINI JA, DAVIDSON BL: Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. (2005) 25(41):9321-9327.
  • KAROLEWSKI BA, WOLFE JH: Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol. Ther. (2006) 14(1):14-24.
  • GHODSI A, STEIN C, DERKSEN T, MARTINS I, ANDERSON RD, DAVIDSON BL: Systemic hyperosmolality improves β-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp. Neurol. (1999) 160(1):109-116.
  • OHASHI T, WATABE K, UEHARA K, SLY WS, VOGLER C, ETO Y: Adenovirus-mediated gene transfer and expression of human β-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA (1997) 94(4):1287-1292.
  • SAKURAI K, IIZUKA S, SHEN JS et al.: Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Gene Ther. (2004) 11(19):1475-1481.
  • FU H, SAMULSKI RJ, MCCOWN TJ, PICORNELL YJ, FLETCHER D, MUENZER J: Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol. Ther. (2002) 5(1):42-49.
  • BERGES BK, YELLAYI S, KAROLEWSKI BA, MISELIS RR, WOLFE JH, FRASER NW: Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing β-glucuronidase. Mol. Ther. (2006) 13(5):859-869.
  • BOSCH A, PERRET E, DESMARIS N, TRONO D, HEARD JM: Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. (2000) 11(8):1139-1150.
  • FRISELLA WA, O'CONNOR LH, VOGLER C et al.: Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther. (2001) 3(3):351-358.
  • WATSON G, BASTACKY J, BELICHENKO P et al.: Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther. (2006) 13(11):917-925.
  • ELLIGER SS, ELLIGER CA, AGUILAR CP, RAJU NR, WATSON GL: Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. (1999) 6(6):1175-1178.
  • CIRON C, DESMARIS N, COLE MA et al.: Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. (2006) 60(2):204-213.
  • HENNIG AK, OGILVIE JM, OHLEMILLER KK, TIMMERS AM, HAUSWIRTH WW, SANDS MS: AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol. Ther. (2004) 10(1):106-116.
  • KAMATA Y, OKUYAMA T, KOSUGA M et al.: Adenovirus-mediated gene therapy for corneal clouding in mice with mucopolysaccharidosis type VII. Mol. Ther. (2001) 4(4):307-312.
  • LI T, DAVIDSON BL: Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA (1995) 92(17):7700-7704.
  • HO TT, MAGUIRE AM, AGUIRRE GD et al.: Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J. Gene Med. (2002) 4(6):613-621.
  • MATTE U, YOGALINGAM G, BROOKS D et al.: Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol. Genet. Metab. (2003) 78(1):37-43.
  • PONDER KP, WANG B, WANG P et al.: Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol. Ther. (2006) 14(1):5-13.
  • DI DOMENICO C, VILLANI GR, DI NAPOLI D et al.: Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum. Gene Ther. (2005) 16(1):81-90.
  • DI DOMENICO C, DI NAPOLI D, GONZALEZ Y et al.: Limited transgene immune response and long-term expression of human α-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum. Gene Ther. (2006) 17(11):1112-1121.
  • BROWN BD, VENNERI MA, ZINGALE A, SERGI SERGI L, NALDINI L: Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. (2006) 12(5):585-591.
  • GAO C, SANDS MS, HASKINS ME, PONDER KP: Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol. Ther. (2000) 2(3):233-244.
  • KOSUGA M, TAKAHASHI S, SASAKI K et al.: Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4Ig coexpression. Mol. Ther. (2000) 1(5):406-413.
  • BAILEY SI, HOWE SJ, SCHAMBACH A, KINNON C, BAUM C, THRASHER AJ: Novel γ-retroviral vectors for gene therapy of SCID-X1. Mol. Ther. (2006) 13:S256.
  • NIENHUIS AW, DUNBAR CE, SORRENTINO BP: Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. (2006) 13(6):1031-1049.
  • THEMIS M, WADDINGTON SN, SCHMIDT M et al.: Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. (2005) 12(4):763-771.
  • MODLICH U, BOHNE J, SCHMIDT M et al.: Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood (2006) 108(8):2545-2553.
  • MONTINI E, CESANA D, SCHMIDT M et al.: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. (2006) 24(6):687-696.
  • CALOS MP: The phiC31 integrase system for gene therapy. Curr. Gene Ther. (2006) 6(6):633-645.
  • DONSANTE A, VOGLER C, MUZYCZKA N et al.: Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. (2001) 8(17):1343-1346.
  • DONSANTE A, MILLER DG, LI Y et al.: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317:477.
  • MALIK P, ARUMUGAM PI, YEE JK, PUTHENVEETIL G: Successful correction of the human Cooley's anemia {β}-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann. NY Acad. Sci. (2005) 1054:238-249.
  • BLUMENTHAL M, SKELTON D, PEPPER KA, JAHN T, METHANGKOOL E, KOHN DB: Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice. Mol. Ther. (2007) 15(1):183-192.
  • POWELL JS, RAGNI MV, WHITE GC et al.: Phase I trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102(6):2038-2045.
  • MANNO CS, PIERCE GF, ARRUDA VR et al.: Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. (2006) 12(3):342-347.
  • MEIKLE PJ, GRASBY DJ, DEAN CJ et al.: Newborn screening for lysosomal storage disorders. Mol. Genet. Metab. (2006) 88(4):307-314.
  • WANG D, EADALA B, SADILEK M et al.: Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns. Clin. Chem. (2005) 51(5):898-900.
  • ANSON DS, MCINTYRE C, THOMAS B et al.: Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Genet. Vaccines Ther. (2007) 5:1.
  • ELLIGER SS, ELLIGER CA, LANG C, WATSON GL: Enhanced secretion and uptake of β-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol. Ther. (2002) 5(5):617-626.
  • KAMATA Y, TANABE A, KANAJI A et al.: Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene. Ther. (2003) 10(5):406-414.
  • KANAJI A, KOSUGA M, LI XK et al.: Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer. Mol. Ther. (2003) 8(5):718-725.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.